Page last updated: 2024-12-07

2-(n-morpholino)ethanesulfonic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2-(N-morpholino)ethanesulfonic acid: RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

2-(N-morpholino)ethanesulfonic acid : A Good's buffer substance, pKa = 6.15 at 20 degreeC. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID78165
CHEMBL ID1234276
CHEBI ID39005
SCHEMBL ID6200
MeSH IDM0045657

Synonyms (82)

Synonym
BB 0258583
CHEMBL1234276
unii-2gnk67q0c4
2gnk67q0c4 ,
brn 0141319
einecs 224-632-3
nsc 157116
morpholinoethanesulfonic acid
ai3-62517
smr000033679
MLS000047669
2-morpholin-4-ylethanesulfonic acid
2-(n-morpholino)ethanesulfonic acid
morpholino-n-ethylsulfonate
4-morpholineethanesulfonic acid
morpholineethanesulfonic acid
4-morpholinethanesulfonic acid
nsc157116
ethanesulfonic acid, 2-morpholino-
4432-31-9
MES ,
mes (buffering agent)
nsc-157116
2-morpholinoethanesulfonic acid
2(n-morpholino) ethane sulfonic acid
mes, low moisture content, >=99% (titration)
DB03814
1A7T
2-(n-morpholino)ethansulfonsaeure
2-(morpholin-4-yl)ethanesulfonic acid
2-morpholinoethanesulphonic acid
2-(n-morpholino)aethansulfonsaeure
2-(4-morpholinyl)ethanesulfonic acid
CHEBI:39005 ,
STL069278
AKOS001483157
FT-0660592
M0606
2-(morpholin-4-yl)ethane-1-sulfonic acid
EN300-85906
BMSE000787
2-(4-morpholino)ethanesulfonic acid
2-(4-morpholinyl)-1-ethanesulfonic acid
BMSE000892
2-(n-morpholino)ethanesulfonic acid hydrate
113834-12-1
2-morpholinoethanesulfonic acid hydrate;2-morpholinoethanesulfonic acid
A826541
BBL012116
137796-01-1
HMS2278K11
FT-0608880
FT-0608879
134549-01-2
EPITOPE ID:158636
mes [mi]
SCHEMBL6200
2(n-morpholino)ethane sulfonic acid
2-(n-morpholino)ethane sulfonic acid
2-morpholino-ethanesulfonic acid
DTXSID4063454
W-106203
HMS3604O20
4-morpholineethanesulfonic acid monohydrate
mfcd00006181
mfcd00283848
mes-buffered saline (5x), ph 6.5
CS-0015168
HY-D0858
3-(n-morpholino)ethane sulfonic acid; mes
3-(n-morpholino)ethane sulfonic acid (mes)
2-morpholinoethane-1-sulfonic acid
2-(n-morpholino)ethanesulfonic acid (mes)
F20304
mes, free acid
Q209294
AS-12613
128655-00-5
potassium hydrotris(3-t-butyl-5-methylpyrazol-1-yl)borate, 97
SY069462
Z1079084978
2-(4-morpholino)ethanesulfonic acid (mes)

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
"To develop a novel intestinal drug absorption system using intestinal epithelial cells derived from human induced pluripotent stem (iPS) cells, the cells must possess sufficient pharmacokinetic functions."( Pharmacokinetic functions of human induced pluripotent stem cell-derived small intestinal epithelial cells.
Imakura, Y; Iwao, T; Kabeya, T; Matsunaga, T; Mima, S; Miyashita, T; Ogura, I; Yamada, T; Yasujima, T; Yuasa, H, 2020
)
0.56
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (3)

ClassDescription
organosulfonic acidAn organic derivative of sulfonic acid in which the sulfo group is linked directly to carbon.
MES
MES
zwitterionA neutral compound having formal unit electrical charges of opposite sign on non-adjacent atoms. Sometimes referred to as inner salts, dipolar ions (a misnomer).
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (4)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Beta-lactamaseEscherichia coli K-12Potency100.00000.044717.8581100.0000AID485294
chromobox protein homolog 1Homo sapiens (human)Potency79.43280.006026.168889.1251AID540317
DNA polymerase eta isoform 1Homo sapiens (human)Potency39.81070.100028.9256213.3130AID588591
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, METALLO-BETA-LACTAMASEBacteroides fragilisKi23,000.000023,000.000023,000.000023,000.0000AID977610
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (15)

Assay IDTitleYearJournalArticle
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID977610Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB1998Biochemistry, May-12, Volume: 37, Issue:19
Unanticipated inhibition of the metallo-beta-lactamase from Bacteroides fragilis by 4-morpholineethanesulfonic acid (MES): a crystallographic study at 1.85-A resolution.
AID1811Experimentally measured binding affinity data derived from PDB1998Biochemistry, May-12, Volume: 37, Issue:19
Unanticipated inhibition of the metallo-beta-lactamase from Bacteroides fragilis by 4-morpholineethanesulfonic acid (MES): a crystallographic study at 1.85-A resolution.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (83)

TimeframeStudies, This Drug (%)All Drugs %
pre-199013 (15.66)18.7374
1990's16 (19.28)18.2507
2000's22 (26.51)29.6817
2010's27 (32.53)24.3611
2020's5 (6.02)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 43.41

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index43.41 (24.57)
Research Supply Index4.44 (2.92)
Research Growth Index4.62 (4.65)
Search Engine Demand Index64.20 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (43.41)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other84 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]